{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:10:01Z","timestamp":1777633801918,"version":"3.51.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The present study summarizes the first experience with <jats:sup>177<\/jats:sup>Lu-PSMA-617 (<jats:sup>177<\/jats:sup>Lu-PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was an analysis of the first 30 consecutive patients who underwent <jats:sup>177<\/jats:sup>Lu-PSMA therapy. Biochemical response was defined as prostate-specific antigen decrease of 50% or greater. Clinical toxicity was based on standardized physician's report, and biochemical and hematological toxicity was graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) criteria. Clinical response was objectified in terms of severity of pain and usage of analgesics after separate treatment cycles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty patients with advanced PCa received therapy cycles with 6 GBq <jats:sup>177<\/jats:sup>Lu-PSMA (median, 4; range, 1\u20136). After the first cycle, usage of analgesics decreased in 45% of the patients. During treatment, maximum prostate-specific antigen decrease was 50% or greater and 90% or greater in 57% and 24% of the patients, respectively. Despite CTCAE grades III and IV anemia occurring in 2 patients (7%), all other newly originated biochemical toxicity was limited to maximum CTCAE grades I and II. Grade II xerostomia occurred in 17% of the patients. During a median follow-up length of 13.7 months (range, 9.8\u201332.3 months), median overall survival from start of the first therapy cycle was 11.3 months (range, 1.4\u201332.3 months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These results confirm the favorable safety and efficacy profile of <jats:sup>177<\/jats:sup>Lu-PSMA, even up to 6 treatment cycles. Therefore, <jats:sup>177<\/jats:sup>Lu-PSMA seems a promising therapeutic strategy for metastatic castration-resistant PCa patients. However, randomized controlled trials are warranted to obtain robust data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002561","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T07:35:02Z","timestamp":1555313702000},"page":"446-451","source":"Crossref","is-referenced-by-count":25,"title":["First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands"],"prefix":"10.1097","volume":"44","author":[{"given":"Ludwike","family":"van Kalmthout","sequence":"first","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Braat","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix","family":"Lam","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"van Leeuwaarde","sequence":"additional","affiliation":[{"name":"Endocrine Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Krijger","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Ververs","sequence":"additional","affiliation":[{"name":"Pharmacy, University Medical Center Utrecht, Utrecht;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Oncology, Radboud University Medical Center, Nijmegen;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan","family":"Bins","sequence":"additional","affiliation":[{"name":"Department of Oncology, Amsterdam University Medical Center, Amsterdam; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmo","family":"Hunting","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Antonius Hospital, Nieuwegein, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[{"name":"Nuclear Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","article-title":"New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib5-20230925","first-page":"9","article-title":"Complex DNA damage: a route to radiation-induced genomic instability and carcinogenesis","volume":"18","year":"2017","journal-title":"Cancers (Basel)"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","year":"1999","journal-title":"Eur J Cancer"},{"key":"bib8-20230925","first-page":"bcr-2018","article-title":"Visual deficit possibly caused by lutetium-177 PSMA treatment","volume":"2018","year":"2018","journal-title":"BMJ Case Rep"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lutetium-177 PSMA radioligand therapy of metastatic castration resistant prostate cancer: safety and efficacy","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib12-20230925","first-page":"114","article-title":"Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study","volume":"5","year":"2015","journal-title":"EJNMMI Res"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.juro.2016.02.2969","article-title":"Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer","volume":"196","year":"2016","journal-title":"J Urol"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration resistant prostate cancer with Lu-177 labeled PSMA-617","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib17-20230925","first-page":"27","article-title":"Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter?","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","year":"2018","journal-title":"EJNMMI Res"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"55094","DOI":"10.18632\/oncotarget.19049","article-title":"Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"177Lu-PSMA radioligand therapy for prostate cancer","volume":"58","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:10:54Z","timestamp":1695618654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201906000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002561","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}